PFO
CYTK icon

Pathstone Family Office’s Cytokinetics CYTK Stock Holding History

Pathstone Family Office’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,603
Closed -$272K – 1514
2022
Q3 		$272K Buy
+5,603
New +$270K ﹤0.01% 1248
2020
Q2 		– Sell
-110
Closed -$1K – 772
2020
Q1 		$1K Buy
+110
New +$1.4K ﹤0.01% 713

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Pathstone Family Office's CYTK Position: Q4 2022 in Review

Pathstone Family Office sold out of Cytokinetics (CYTK) in Q4 2022, closing a stake of 5,603 shares — an estimated $272K sold.

Pathstone Family Office first reported a position in CYTK in Q1 2020 and held it in 2 quarters. The position peaked at $272K in Q3 2022. 277 funds tracked by Wall St. Rank hold CYTK as of Q4 2022.

  • Pathstone Family Office reported no remaining Cytokinetics position as of Q4 2022 after selling out during the quarter.
  • Pathstone Family Office sold 5,603 Cytokinetics shares in Q4 2022, an estimated $272K.
  • Pathstone Family Office first reported a position in Cytokinetics in Q1 2020 and held it in 2 quarters.
  • Pathstone Family Office's Cytokinetics position peaked at $272K in Q3 2022.
  • 277 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2022.

Based on Pathstone Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.